Overview
Camino Science is a biotech company that develops an in silico platform to accelerate in vitro experiments through advanced algorithms that analyze biological data. Their technology aids researchers, pharmaceutical companies, and agricultural industries in drug discovery, optimizing crop yields, and addressing global challenges. They focus on identifying protein functions and interactions, which enhances the R&D process by prioritizing insights for testing.
Financials
Revenue history (in k)
Filing timeliness
Financial statements were filed on time, on average 20 days early. 4 of 6 audited by a statutory auditor.
- 202515/07/2026
- 202406/07/2025
- 202314/07/2024
- 202215/07/2023
- 202101/07/2022
- 202014/07/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Authorized Representatives
Manner of representation
In the case of a one-person management board – the member of the management board. In the case of a management board consisting of two or more persons – joint action by two members of the management board, or by one member of the management board together with a commercial proxy.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Mariusz Ferencage 51 | 1,008 | $13,614.26 | 80% |
Bartłomiej Sawulskiage 51 | 252 | $3,403.57 | 20% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2020-04-24.
12 1020 1332 0000 1002 1231 2577
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 30, 2021 | Aid for SME access to finance — aid for start-ups | $218.5K$218,488 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Nov 6, 2020 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $1,069$1,069 | PREZYDENT MIASTA GDYNIA |
European Funds
3 projects recorded: 1 from FE lists ($218,488) and 2 Commission grants (FTS) ($1,779,200).
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2023-01-01 | 190103838 - In silico bio-evolutio - in silico bio-evolutio - novel ai paradigm for molecular biology | $1.2M$1,245,440 | 1.0.11 - Horizon Europe | |
| 2023-01-01 | 190103838 - In silico bio-evolutio - in silico bio-evolutio - novel ai paradigm for molecular biology | $533.8K$533,760 | 1.0.11 - Horizon Europe | |
| 2021-05-01 | InSilico Camino - an AI-based platform that predicts in silico experiments on in vitro viruses. | $218.5K$218,488 | Operational Programme Eastern Poland |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Upside Labsp. z o.o. | $1,468,774.96 | upsidelab.io | ||
| Wislacode SolutionsP.S.A. | $776,419.31 | wislacode.com | ||
| Animativsp. z o.o. | $701,101.44 | animativ.pl | ||
| Coderspeaksp. z o.o. | $696,322.10 | coderspeak.com | ||
| Esensivesp. z o.o. | $514,565.61 | esensive.com | ||
| Istarssp. z o.o. | $533,964.95 | internetstars.pl | ||
| Bards.Aisp. z o.o. | $471,690.60 | bards.ai | ||
| BrainscanS.A. | $411,063.49 | brainscan.ai | ||
| Network Perspectivesp. z o.o. | $333,080.51 | networkperspective.io | ||
| QZ Solutionssp. z o.o. | $245,519.36 | qzsolutions.pl |
Change history
| Date | Event | |
|---|---|---|
| 2020-11-26 | Share capital increase (5,000.00 PLN → 63,000.00 PLN) | |
| 2020-03-25 | Entered in the register |
FAQ
Last updated: 2026-07-16